Guardant Health, Inc. (GH)
| Market Cap | 13.01B |
| Revenue (ttm) | 323.65M |
| Net Income (ttm) | -378.65M |
| Shares Out | 101.30M |
| EPS (ttm) | -3.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 409,022 |
| Open | 128.50 |
| Previous Close | 129.32 |
| Day's Range | 126.40 - 129.32 |
| 52-Week Range | 96.66 - 181.07 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 167.38 (+30.4%) |
| Est. Earnings Date | Nov 4, 2021 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the e...
Financial Performance
In 2020, GH's revenue was $286.73 million, an increase of 33.75% compared to the previous year's $214.38 million. Losses were -$253.78 million, 235.5% more than in 2019.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price forecast is 167.38, which is an increase of 30.36% from the latest price.
News
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensi...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance,...
New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360® Liquid Biops...
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the adva...
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the upco...
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming UBS Genomics 2.0 and Me...
Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management Updates
After the market close on Thursday, Guardant Health Inc (NASDAQ: GH) reported Q2 revenues increased 39% Y/Y to $92.1 million, beating the consensus of $84.61 million. Guardant's oncology testing revenue...
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of -10.34% and 8.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Dire...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced a new leadership structure to support the Company's strategic objectives fo...
Guardant Health Reports Second Quarter 2021 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data...
Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to Decline
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorecta...
SPRINGFIELD, Mo. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Fight Colorectal Cancer (Fight CRC), the nation's leading colorectal cancer (CRC) patient advocacy organization, and Guardant Health, Inc. (Nasd...
AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round
SEOUL, Souh Korea, July 19, 2021 /PRNewswire/ -- Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of $26 million from Guardant Health, Inc. (Nasdaq: GH)...
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2021 after market...
New Strong Sell Stocks for July 7th
ACCD, DNLI, FSLY, FHB and GH have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2021.
This Explosive Biotech Is Taking On a Huge New Market
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late-stage and metastatic cancers. The Gu...
CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy i...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Please replace the release dated May 19, 2021 with the following corrected version due to a change in the fourth paragraph. The updated release reads: GUARDANT HEA...
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Chris Freeman as the company's new Chief Commercial Of...
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021, s...
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen's LUMAKRAS™ (so...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx test as the first and only liquid b...
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today filed a lawsuit against Natera, Inc. for false advertising, unfair competition, and...
Where Guardant Health Stands With Analysts
Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 0 1 Somewhat Bullish 1 1 0 2 Indifferent 0 ...
With Expenses Growing Faster Than Revenue, Is This Cathie Wood Stock in Trouble?
Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses.
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen's RYBREVANT™ (amivantamab-vmjw) for Use in...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as the first and...